Liver Cirrhosis
Conditions
Interventions
Patietns will receive 3 capsules of Nobelzin (zinc acetate, 1 capsule includes 50mg zinc) per day for 12 weeks
Patietns will receive 3 capsules of placebo per day for 12 weeks
Sponsors
Ministry of Health, Labour and Welfare
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Liver Cirrhosis 2.Hyperammonemia >= ULN (more than 2 times within the past 2 months) 3.Hepatic coma grade <= 2 4.Serum levels of zinc <= 65 microgram/dl 5.Ages 20 or older 6.Out-clinic patients
Exclusion criteria
Exclusion criteria: 1.Hepatic coma grade >= 3 2.Fulminant hepatitis 3.Patients with malignant diseases who need to be treated during the period of this trial 4.Patients with cardiac, renal or pancreatic diseases who need admission for the therapy 5.Patients who are associated with heavy hematological disorders or cerebrovascular diseases 6.Known or suspected history of allergy to zinc 7.Inegible patients at a physician's discretion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum levels of ammonia (0-week and 12-week) Adverse effects(during trial, 0-12 week) | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum levels of BTR, psychometric testing, hepatic coma grade (0-week and 12-week) | — |
Countries
Japan
Contacts
Public ContactRyujin Endo
Iwate Medical University, School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine
Outcome results
None listed